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Inducing T cell responses by therapeutic vaccination requires appropriate activation
of antigen presenting cells (APCs). The use of virus-like particles (VLPs) containing
Toll-like receptor (TLR) ligands has demonstrated remarkable potential in activating
APCs and modulating the immune response both for prophylactic vaccines as well
as immunotherapy. Here, we employed VLPs associated to TLR ligands as tools to
modulate cytotoxic response mediated by CD8+ T cells and provide further insight
in the development of T cell-based immunotherapy. We have investigated the in vivo
transcriptional signature in dendritic cells (DCs) from mice immunized with VLPs
containing distinct classes of nucleic acid and correlated the expression patterns with
the efficiency of induced T cell responses. We identified key pathways activated in DCs
that are involved in the appropriated induction of T cell responses and show evidence for
the modulatory effect of CCL2 in CD8+ T cells responses. These insights shed light on
immune networks that are pivotal for the induction of potent cytotoxic T cell responses
and identify key genes for appropriate DC activation and subsequent modulation of the
adaptive immune response.
Keywords: VLP (virus-like particle), CpG—oligonucleotides, dendritic cell (DC), T cell—DC interactions, CCL2
INTRODUCTION
In spite of all prophylactic vaccines in use to date promoting protection through neutralizing
antibodies, there is a growing interest in developing vaccines that induce protection mediated
by T cells. Therapeutic vaccines against chronic viral infections and cancer in particular, seem
to benefit from the induction of T cell responses, in particular cytotoxic responses mediated
by CD8+ T lymphocytes (CTL) (1–3). However, unlike some vaccines that induce neutralizing
antibody responses and have been developed empirically, induction of effective antigen-specific
T cell responses has proved itself a complex endeavor that will require major developmental
strides before reaching the market (4). Considering the distinct regulation and complexity of the
activation events for B and T lymphocytes, it is reasonable to assume that unlike B cell inducing
vaccines, attempts to develop T cell inducing vaccines will not be successful until we have a better
understanding of the regulatory networks of T cell responses. T cell responses are tailored by the
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innate immune system through costimulatory and inhibitory
molecules and cytokine/chemokine clues mostly promoted by
antigen presenting cells (APCs), especially DCs (5). Appropriate
activation of APCs is critical for successful vaccine development
strategies since APCs are responsible not only for initiating
but also sustaining the adaptive immune response. Therefore,
understanding the factors that drive appropriate activation of
APCs that correlate to the adaptive response becomes paramount
for vaccine development, especially when aiming for T cell
mediated protection.
The process of developing safer vaccines has in most cases
rendered antigenic candidates less immunogenic. Thus, the
search for an appropriate adjuvant—i.e., an adjuvant that will
modulate the response toward the desired outcome—can be
considered almost as important as the choice of the antigenic
target during vaccine development. TLR ligands have emerged
as a promising adjuvant for vaccines due to their safety and
remarkable ability to enhance immunogenicity with efficacy
already proven in the clinics (1, 6, 7). TLR7/8 and TLR9
ligands, such as ssRNA and CpG, especially in combination
with delivery systems such as nanoparticles and VLPs, have
been showing promising results in the induction of cytotoxic
T cells and have been successfully employed in a plethora of
pre-clinical vaccines for different indications. Understanding the
initial events induced by TLR-ligands, in particular in DCs, can
be a valuable tool for the development of effective adjuvants
and therapeutic vaccines. To gain insight into these early events,
we have employed systematic and integrative analysis of in vivo
gene expression in DCs preceding three types of CD8+ T cell
responses after vaccination: (i) absent vs. (ii) inefficient vs. (iii)
protective T cell responses. We have previously demonstrated
that VLPs containing B type CpG are able to induce protective T
cell responses in tumor models caused by human papilloma virus
(HPV) (8) and viral infections (9) while its VLP counterparts
containing RNAwere unable to provide protection against tumor
growth and associated mortality. Using the same vaccine model,
we have investigated the transcriptional signature in DCs the first
day following immunization in vivo with these different vaccines
and correlated the initial events and pathways to cross-priming
of T cells by DCs.
MATERIALS AND METHODS
VLPs, Vaccine Preparation
and Immunizations
Qβ VLPs were prepared as previously described (8). Packaging
of CpG B into Qβ VLPs was performed by digestion of
bacterial RNA with RNAse A (Merck). RNAse-treated VLPs were
either further purified to remove RNAse and degraded RNA to
make VLPs devoid of nucleic acid [Qβ(o)] or combined with
CpG. Excess of CpG and RNAse was removed by dyafiltration
(Amicon). Packaging of CpG A G10 was performed by re-
assembling as previously described (10). Re-packaging and
integrity of VLPs were assessed by co-localization of nucleic
acid and protein on a native agarose gel stained with SYBR safe
(Invitrogen), followed by Coommasie blue stain (Expedon).
Vaccines were prepared by chemical coupling of antigens and
VLPs using the heterobifunctional cross-linker succinimidyl-6-
(β-maleimidopropionamido) hexanoate (SMPH, Pierce, USA)
following manufacturer’s instructions.
Type A CpG G10 were custom made by Eurogentec.
Sequence: 5′gggggggggggacgatcgtcgggggggggg 3′. CpGs 1668
with phosphorothioate backbone were purchased from Invivogen
(sequence: 5′ tccatgacgttcctgatgct 3′). Immunodominant peptides
p33 was produced in a modified version with additional 3
aa (GGC) added to the C terminus (Proimmune, UK) to
allow chemical crosslinking of peptide to VLPs. P33 peptide
sequence: KAVYNFATMGGC.
Mice
Wild-type C57BL/6 mice were purchased from Envigo (UK).
CCL2 knockout mice were described previously (11) and
purchased from Jacksons lab, USA. STING−/− mice was
provided by John Cambier and it have been described elsewhere
(12). MAVS−/− mice has been provided by Jan Rehwinkel and
described elsewhere (13).
All mice used in this study were bred in specific pathogen-
free (SPF) conditions. This study was carried out in accordance
to the recommendations of the Animals (Scientific Procedures)
Act 1986 (ASPA) and European Directive 2010/63/EU on the
protection of animals used for scientific purposes. Protocols were
approved by the Animal Welfare and Ethical Review Bodies
at the Nuffield Department of Clinical Medicine, University of
Oxford (PPL 30/2947).
Cells Preparation and Sorting
Spleens were isolated at indicated time-points and prepared
for analysis.
Cell sorting—Sorting of splenic DCs was performed with
immunomagnetic positive selection of mouse CD11c+ cells
(EasySep Mouse CD11c, StemCell Tech) according to the
manufacture’s instruction.
Conventional bone-marrow derived DCs (BMDCs) and bone-
marrow derived plasmacytoid DCs (BMpDCs) generation—bone
marrow cells were cultured in complete RPMI for 6–8 days in the
presence of granulocyte-macrophage colony-stimulating factor
(GM-CSF) containing X-63 cell supernatant for generation of
conventional BMDCs or FLT3 (Insight Biotech) for generation
of BMpDCs.
Tetramer Staining and
Cytokine Measurement
Total splenocytes of immunized mice were isolated 24 h
following immunization and single-cell suspension was prepared
as and cultured for further 12 h. Secreted cytokines (G-CSF, GM-
CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9 IL-10,
IL-12p40, IL-12p70, IL-13, IL-17, CCL2, CCL3, CCL5, CXCL1,
CXCL2, CXCL10) were measured with a Milliplex kit (Merk-
Millipore, France) following the manufacturer’s instructions.
Luminex MAGPIX system with xPONENT software was used
for data acquisition and data analysis. INF-α, IL-12p40/70,
and IL-1α/β were measured by ELISA following manufacturer’s
instruction (Thermo Fisher, R&D, and R&D, respectively).
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T cell response was assessed 7 days following immunization.
For tetramer staining freshly isolated splenocytes were stained
and immediately analyzed with anti-CD8 and p33 Tetramer. For
cytokine production, cells were re-stimulated with p33 peptides.
Antibodies and Flow Cytometry
Flow cytometry was performed using a BD FACSCanto II and the
following antibodies:
APC-Cy7 anti-CD11c (N418, Invitrogen), PerCP-Cy5.5 anti-
CD3, AlexaFluor700 anti-CD8, FITC anti-TNFα (eBioscience),
APC anti-IFNγ (Life Tech), PE anti-CD101 (Thermo), PE
anti-CD86 (eBioscience), Acqua Live-Dead dye (Thermo),
FITC anti-CD40, APC conjugated Tetramer-p3333−41 (H-2D
b
KAVYNFATC, NIH core tetramer facility) were used.
For intracellular staining of IFN-γ, IL-12, and TNF-α,
splenocytes were fixed and permeabilized with BD Cytofix buffer.
Antibody staining was performed subsequently to Fc receptor
blockade (monoclonal antibody 2.4G2 to mouse CD16-CD32,
10µg/ml) in PBS supplemented with 0.1% FBS.
Data analysis was performed in the FlowJo
software (TreeStar).
Immunofluorescence and Endosomal
Trafficking of VLPs and Free CpG
Cells were cultured on glass-bottom, 0.17mm tissue culture
dishes (MatTek GLASS). BMDCs were incubated with
CellLight R© Lysosomes-GFP following the manufacturer’s
instructions (Life Technologies). Qβ VLP were packaged with
a type B CpG 1668 coupled to a fluorescent dye (custom
made, Eurogentec). Confocal microscopy studies were
performed with an oil immersion objective (63x oil immersion,
numerical aperture 1.4) on Zeiss LSM 710 Multiphoton
Confocal Microscope.
Type B CpG sequence and modifications: 5′
tccatgacgttcctgatgct 3′ coupled to AlexaFluor 547 dye. Packaging
of CpG-AF547 was performed as described previously on this
manuscript for unlabelled CpG.
RNA Preparation, RNA-seq and Primary
Data Analysis
Sample preparation - Total RNA was extracted from sorted
splenic DCs from immunized mice following the manufacturer’s
protocol (RNeasyMidi Kit, Qiagen), using an on-columnDNase-
I digest step.
Material was quantified using RiboGreen (Invitrogen) on the
FLUOstar OPTIMA plate reader (BMG Labtech) and the size
profile and integrity analyzed on the 2,200 or 4,200 TapeStation
(Agilent, RNA ScreenTape). Library preparation was completed
using TruSeq Stranded Total RNA kit (Illumina) following
manufacturer’s instructions. Libraries were amplified on a Tetrad
(Bio-Rad) using in-house unique dual indexing primers (14).
Individual libraries were normalized using Qubit, and the size
profile was analyzed on the 2,200 or 4,200 TapeStation. Individual
libraries were normalized and pooled together accordingly. The
pooled library was diluted to ∼10 nM for storage. The 10 nM
library was denatured and further diluted prior to loading on
the sequencer. Paired end sequencing was performed using
a HiSeq4,000 75bp platform (Illumina, HiSeq 3,000/4,000 PE
Cluster Kit and 150 cycle SBS Kit).
Data analysis - All statistical and bioinformatics analysis
was performed using R language (https://www.r-project.org) and
Bioconductor packages.
Trimmomatic 0.35 package was used in order to quality filter
reads and remove adapter contamination (15). The first 10 and
the last base were removed after visual inspection of the read
quality distribution. After trimming, read length was 64BP.
For read mapping, Star aligner v2.5.2b (16) was used
on the Gencode M12 transcriptome (mm 10) with settings
“–outSAMmultNmax 20.” Reads were assigned to genes using
featureCounts v1.5.1 (17) with settings “-C -B -M -s 2 -p”. To
calculate log2 fold change estimates between groups, a negative
binomial general linear model was fit using DESeq2 (18) and only
genes with a Benjamini-Hochberg (19) corrected Wald test FDR
of less than 5% were labeled significant.
The overrepresentation of pathways within groups of DE
genes was computed by applying a one-tailed Fisher’s exact test.
Only top-level pathways with P < 0.0001 for overrepresentation
were considered. Plots were generated in R language with the
package ggplot2.
Heatmaps were generated using counts per million multi
mapped (CPM-MM) values as input. CPM-MM values are mean
centered, row scaled and standardized. Hierarchical clustering
was performed by using the distance based Euclidean distances
using complete linkage clustering.
RESULTS
Packaging of CpGs Into VLPs Alters
Endosomal Trafficking and
Immune Responses
Considering the distinct immune responses induced by the
three classes of CpG (20, 21) and the widespread use of CpG
associated to nanoparticles, we wanted to evaluate the impact
of packaging different classes of CpG—type A and type B—into
VLPs in the context of T cell-inducing vaccines [for a review
on different types of CpG see (6)]. Hereafter, VLPs packaging
CpG will be represented by Qβ(G10) for type A CpG G10, and
Qβ(1668) for type B CpG 1668, an schematic representation of
re-packing process and quality assessment of re-packed VLPs
are demonstrated on Figures 3A,B. To compare the ability of
Qβ(G10) and Qβ(1668) to induce T cell responses, VLPs were
cross-linked with the immunodominant model peptide p33,
derived from Lymphocytic Choriomeningitis virus (LCMV).
Mice were immunized and CTL responses assessed by tetramer
staining 7 days later (Figure 1A). Mice receiving Qβ(1668)-p33
had at least 3-fold higher frequencies of p33-specific T cells
compared to Qβ(G10) (Figure 1B).
To further investigate the differences on CTL responses
generated by CpG A G10 vs. CpG B 1668, the initial activation
of DCs induced by each CpG was evaluated. To that end,
freshly isolated splenocytes or bone marrow derived pDCs and
cDCs were stimulated for 24 h and activation markers and
cytokines were measured in response to free CpGs and their
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packaged counterparts. The activation molecule CD86 was up-
regulated in DCs in response to all preparations, however free
type B CpG was found to be superior at inducing CD86 up-
regulation especially in pDCs, where a more striking difference
was observed (Figure 2A). TNF-α was produced mostly by pDCs
and at higher levels by the cells treated with free type B CpG
or the VLPs compared to type A CpG (Figure 2B). IL-12, a key
cytokine associated with Th1 response and known to be induced
at high levels by type B CpG was produced at different levels
depending not only on the stimuli but also on the cell type being
FIGURE 1 | CpG B 1668 is superior than CpG A G10 at inducing CTL
responses. (A) Immunization schedule. Mice were immunized s.c. with 50 µg
of Qβ containing either G10 type A CpG (Qb(G10)-p33), or 1668 B type CpG
Qβ(1668)-p33. Spleens were collected 7 days later and p33 antigen-specific
CD8+ T cells were analyzed by (B) p33-specific Tetramer staining. Data
represented as mean + SEM. N = 3 mice.
investigated (Figures 2C,D). cDCs produced higher levels of IL-
12 in comparison to pDCs in response to all stimuli. When
measuring IL-12 produced by total splenocytes (Figure 2D), a
different trend was observed with higher levels of IL-12 being
produced in response to free CpGs most likely due to B cells that
are also express TLR9.
It has been previously described that CpGs associated
with liposomes trigger distinctive immune responses when
compared to free molecules due to distinct spatial-temporal
distribution of the CpG/liposome, which dictates the interaction
of CpGs with components of the signaling cascade of TLRs
(22). To investigate whether the same phenomena would be
influencing the cytokine production observed here, a time-
lapse experiment of CpG uptake by BMDCs was performed
by pulsing cells with the type B CpG 1668 containing a
fluorescent dye. We found that free CpG co-localizes with the
lysosomal marker LysoTrack as fast as 6min after addition
of CpG to the cells (Figure 3C). Next, the spatiotemporal
distribution of Qβ(1668) was tested in a similar setting. To
that end, BMDCs were pulsed with the VLP containing CpG
coupled to a fluorescent tag, washed, and fixed at the indicated
time points (Figure 3D). Co-localization of packaged CpG and
LysoTrack dye was delayed in comparison to the free CpG.
At the 10min time-point (Figure 3D upper panel), no co-
localization was observed between CpG and the LysoTrack
dye, as evidenced in the 2D intensity histogram of the co-
localization of pixels in each of the two analyzed channels.
FIGURE 2 | Packaging of CpGs on VLP alters the immune response induced by VLPs. (A) CD86 expression and (B) TNF-α production by splenic pDCs and cDCs.
(C) IL-12 production by splenic cDCs (CD11c+CD317-) and pDCs (CD11c+CD317+) treated with 1µM of the respective CpG or 100µg/mL of VLP for 24 h. (D)
IL-12 production by murine splenocytes incubated with either 1µM of the free CpG or 100µg/mL of the respective VLP for 24 h. Data represented as Mean + SEM,
n = 3 mice for splenocytes and for BMDCs, pooled bone marrow of 2 mice with 3 biological replicates per condition. Statistical significance was measured by ANOVA
followed by multiple t-tests followed by Bonferroni and Dunn’s correction for multiple testing ***p < 0.001, *p < 0.01.
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FIGURE 3 | Packaging CpGs into VLPs alters endosomal trafficking of CpG. (A) Schematic representation of re-packaging of VLPs with polyanionic molecules. (B)
Re-packaging of VLPs analyzed by co-localization of protein and nucleic acid in a native agarose gel stained with SYBR safe for nucleic acid (upper panel) and
Coomassie for proteins (lower panel). First lane shows the migration pattern of a purified and intact VLP packaging RNA. Lane 2 and 3 with samples from the reduced
and disassembled VLP. 4 and 5 shows the re-assembled VLPs with A type CpG and B type CpG. (C) Time-lapse of in vitro uptake of free CpG 1668 by BMDCs.
Lysosomes is represented in green (GFP), CpG in red (Alexa Fluor 567). (D) Endosomal trafficking of B type CpG packed into Qβ VLP. BMDCs were pulsed with the
VLP for 10min (upper panel) or 20min (bottom panel), washed and immediately fixed. First image in green shows the endosomal compartment, followed by the CpG
channel. Third image contains the superposition of both channels (plus DAPI stain for the nuclei). 2D intensity histogram showing pixel co-localization of the two
channels. Data is representative of 3 independent experiments.
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FIGURE 4 | Packaging of CpGs on VLP alters the immune response induced by VLPs. C57BL/6 mice were vaccinated s.c. with 50 µg of VLP-p33 containing RNA
(E. coli), CpG class B or the empty capsid. (A,B) p33-specific tetramer staining of CD8+ T cells from 3 immunized mice and (C) ICS staining of CD3+CD8+ T cells 7
days post vaccination. 6 h stimulation with p33 peptide from 5 immunized mice. Data represented as Mean ± SEM. Statistical significance was measured by unpaired
two tailed t-tests followed by Bonferroni-Dunn’s correction for multiple testing. *p < 0.01, ***p < 0.0009. Data is representative of 3 independent experiments.
Only at a later time-point (20min), extensive co-localization
could be detected, demonstrating that CpG reach the lysosomal
compartment in a delayed fashion if packaged into VLPs. Thus,
packaging CpG into VLP alters their endosomal trafficking,
which may explain the distinct immune responses induced
in DCs.
Qβ Packaging Type B CpG Induces
Superior Antigen-Specific CD8+ T Cell
Responses Compared to Qβ
Packaging RNA
It has been consistently shown in the literature that VLP-based
vaccines containing CpG are able to induce strong immune
responses and enhance protection in different challenge models.
For instance, Qβ(1668) coupled to a LCMV-derived peptide
or HPV-derived E7 protein had shown excellent protection in
viral (5) and tumor models (8), respectively. The consistently
superior ability of Qβ(1668) in comparison to Qβ(RNA) to
induce protection in different models in a CTL-dependent
manner propelled us to further investigate the initial events in
the immune response that were leading to appropriate activation
of T cells.
To demonstrate the distinct induction of T cell responses
promoted by type B CpG (TLR9 ligand), RNA (TLR7/8 ligand)
or in absence of TLR stimulation in vivo, Qβ(1668), VLPs
containing prokaryotic RNA [represented as Qβ(RNA)], and
VLP devoid of nucleic acid [as Qβ(o)] were cross-linked
to the immunodominant LCMV-derived peptide gp3333−41
and mice were immunized via the s.c. route. The antigen
specific CTL response was evaluated 7 days after immunization
(Figures 4A,B). Packaging of type B CpG into VLPs had not
only increased the expansion of p33-specific T CD8+ cells
as previously demonstrated by tetramer staining (Figure 1B)
but had also boosted the amount of key cytokines such as
IFN-γ and TNF-α being produced in response to antigen
stimulation (Figure 4C). Qβ(RNA) also induced antigen-specific
T cell responses and cytokine production but to a much lesser
extent when compared to Qβ(1668). VLPs devoid of nucleic
acids, on the other hand, induced responses comparable to
naïve mice. Additionally, mice lacking cytoplasmic nuclei-acid
sensors stimulator of interferon genes (STING, also known as
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FIGURE 5 | Continued
Myps and TMEM173), the adaptor molecule of the retinoic
acid-inducible gene-I-like receptors (RIG-I) and mitochondrial
antiviral protein (MAVS) were immunized following the same
regimen and no statistically significant differences were observed
in T cell responses, ruling out a role for such sensors in T cell
responses induced by VLPs loaded with TLR7/8 or 9 ligands
(Figure S1).
Transcriptional Signature in Splenic DCs
24h Post Immunization With VLPs
Containing TLR9 or TLR7 Ligands
as Adjuvants
To evaluate the impact of the nucleic acid packaged within the
VLP on the innate immune response, mice were immunized
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FIGURE 5 | Transcriptional reprograming of DCs 24 h after immunization. (A)
Volcano plot of genes differently expressed between Qβ(RNA) vs. Qβ(o), Qβ(o)
vs. Qβ(1668), and Qβ(RNA) vs. Qβ(1668), respectively. Log2 fold change on
the x-axis and the -Log10 p-values on y-axis. Up-regulated genes are
represented in red and down-regulated gene in green. (B) Number of genes
differently expressed between the groups with a FDR of 10%. (C) Principal
component analysis of genes differently expressed among the groups. The
effects of the principal component 1 (PC1) is shown on x-axis and principal
component 2 (PC2) shown in the y-axis (D) Genes with major contribution to
sample clustering. (E) top 30 differently expressed genes. Hierarchical
clustering of top 30 differently expressed genes. Regularized log transformed
count data were row scaled and hierarchical clustering was applied to
Euclidean distances using complete linkage clustering.
with 50 µg of the respective VLP and 24 h later spleens
were collected and processed for analysis. Total RNA was
extracted from sorted CD11c+ murine splenic cells. Following
rigorous quality control, RNA samples were analyzed by
genome-wide RNA-sequencing.
Mice immunized with VLP devoid of TLR ligands were
used as control for the groups receiving VLPs associated with
TLR ligands. The baseline normalized log2 gene expression
values for genes with a significant change in expression between
groups (adjusted P < 0.05 FDR) were classified as differentially
expressed genes (DEGs). The differential expression of these
genes was analyzed for statistical significance by one-way analysis
of variance (ANOVA).
VLPs loaded with a TLR-ligands (CpG 1668 or RNA)
led to differential expression of more than 3,800 genes in
comparison to the formulation devoid of TLR (3,855 genes
between Qβ(1668) vs. Qβ(o) and 4,504 genes between Qβ(RNA)
vs. Qβ(o), showing the major transcriptional changes that TLR
engagement promotes on the cell, while Qβ(RNA) vs. Qβ(1668)
had far fewer genes differently expressed, with 279 genes in
total (Figures 5A,B).
Later, aiming to assist the characterization and understanding
of the regulation of genes controlling the immune
response, an unsupervised principal component analysis
(PCA) was performed on the data set and revealed an
expected clustering of samples according to the type of
PRR ligand packaged within the VLP (Figures 5C,D).
Considering that the three groups had received the
same VLP packaging different TLR-ligands, the genes
most significantly contributing to the clustering of the
samples (Figures 5C,D) can be attributed to the distinct
transcriptional signature triggered by the TLR ligands and not
the VLP itself.
The top 30 differently expressed genes between the groups
were analyzed for hierarchical clustering performed by
calculating the Euclidean distances using complete linkage
clustering method. Figure 5E shows the top 30 genes differently
expressed between Qβ(1668) vs. Qβ(o). Clustering analysis
showed a distinct expression profile between the three groups
with genes mostly involved in immune responses and TLR
signaling such as the gene coding for the adaptor molecule
Myd88, the alarmins S100a8/9 and members of the family
guanylate binding proteins (GBPs). In addition to genes
involved in immune responses, several genes responsible for
controlling cell homeostasis, cell signaling, and metabolism
were also differently expressed. Examples of note were the
Steap4 and MMP8 genes, two metalloreductase that have
been shown to integrate metabolism and inflammatory
responses (23), and Upp1 (24) an enzyme that catalyzes
events related to transcription and translation of proteins.
It is noteworthy that the major transcriptional changes that
DCs undergo upon TLR engagement are related to either
metabolism or immune responses. This a direct consequence
of the metabolic program that DCs need to undergo in
order to support the immune response, gene transcription
and translation, protein and cytokines production, and cell
migration, which represent major energetic demands for
the cell (25). Surprisingly, Qβ(RNA) clustered closer to
Qβ(o) compared to Qβ(1668), showing the top 30 genes
differently regulated in response to CpG is quite distinct from
RNA-induced responses, despite engagement of TLRs both
driving MyD88-dependent responses.
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FIGURE 6 | Gene set enrichment analysis of differently regulated genes on Qβ(RNA) vs Qβ(1668). (A) Gene set enrichment analysis of up-regulated genes). (B) Gene
set enrichment analysis of down-regulated genes. Pathways sharing gene sets are connected by a line. (C) Gene set enrichment analysis of down-regulated genes.
Significance displayed as a color scale as indicated by the p-value. X-axis: number of genes in the dataset per pathway.
Functional Analysis of Transcriptional
Signature Reveals Important Pathways
Engaged by the Qβ VLP Containing
TLR Ligands
Following the initial characterization of the transcriptional
regulation, additional data mining methods were employed to
facilitate the identification of patterns of gene expression at the
system level. Functional enrichment analysis of genes differently
expressed was performed using the ClusterProfile method (26,
27) revealing important immune pathways and genes that
were differentially regulated across the groups. Qβ(1668) and
Qβ(RNA) in comparison to Qβ(o) up-regulated pathways related
to immune system or metabolism, such as cytokine signaling and
biosynthesis of amino acids, respectively (Figure S2).
Qβ(1668) in comparison to Qβ(RNA)-recipient group
(Figure 6) showed that among the 279 differently expressed
genes, relevant immune pathways such as chemokine signaling
pathway and cytokine-cytokine receptor interaction were
enriched. In addition to those general pathways, genes belonging
to the NOD-like receptor pathway such as NLRP12, p38, GBPs,
CCL2, and CCL12 were significantly upregulated by Qβ(1668).
Other pathways involving cytokine and chemokine signaling
and production were also up-regulated, including TNF-α and
IL-17 pathways. Regarding the genes up-regulated by Qβ(RNA),
there was a set of genes belonging to the anti-apoptotic NFκ-B
pathway such as Bcl2a1d (28). We have also performed KEGG
module pathways analysis on genes downregulated on the
Qβ(RNA) vs. Qβ(1668), showing the enrichment of genes
belonging to the modules ECS complex, JAK-STAT signaling,
and Acylglycerol degradation. The complete list of differently
regulated pathways and the genes contributing to the enrichment
of pathways in the comparison of Qβ(RNA) vs. Qβ(1668), are
listed in Table 1.
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TABLE 1 | Enriched pathways on Qβ(RNA) vs. Qβ(1668).
Description Gene ratio Bg ratio p-value p. adjust q-value Gene name Count FC
NF-kappa B
signaling pathway
5/46 104/8263 0.00026092 0.02530903 0.02361993 Relb/Bcl2a1a/Bcl2a1b/
Gadd45b/Bcl2a1d
5 Up
NOD-like receptor
signaling pathway
11/100 168/8263 5.2401E-06 0.00101658 0.00088806 Gbp2/gbp7/nlrp12/CCL2/Gb3/
CCL12/Mapk13/Myd88/Oas2/
Hsp90ab1
11 Down
IL-17 signaling
pathway
8/100 91/8263 1.2895E-05 0.00125084 0.00109271 S100a9/S100a8/CCL2/Lcn2/
CCL12/Mmp9/Mapk13/
Hsp90ab1
8 Down
Influenza A 9/100 168/8263 0.00018687 0.01144463 0.00999775 CCL2/SOCS3/CCL12/22074/
Try4/Mapk13/Myd88/Furin/
Oas2/Hspa8
9 Down
Pancreatic
secretion
7/100 103/8263 0.0002361 0.01144463 0.00999775 Ctrl/Pnliprp1/Amy2b/Try4/Cpa2/
Bst1/Atp2a2
7 Down
Toxoplasmosis 7/100 108/8263 0.00031631 0.01144463 0.00999775 Igtp/SOCS1/Maok13/CCR5/
Irgm1/MyD88/Hspa8
7 Down
TNF signaling
pathway
7/100 110/8263 0.00035396 0.01144463 0.00999775 CCL2/SOCC3/CCL12/Mmp9/
Mapk13/Irf1/Ifi47
7 Down
Chemokine
signaling pathway
9/100 199/8263 0.0006522 0.01807516 0.01579002 CXCR2/CXCR1/CCL2/Pppb/
CCR1/CCL12/CCR5/Jak3/Nras
9 Down
Cytokine-cytokine
receptor
interaction
11/100 296/8263 0.00085723 0.02078771 0.01815964 CXCR2/CXCR1/CCL2/Ppbp/
IL-1f9/CCR1/CCL12/CCR5/
IL12rb1/Csf3r/16190/IL4ra
11 Down
Prolactin signaling
pathway
5/100 72/8263 0.00173004 0.03729202 0.0325774 SOCS3/SOCS1/Mapk13/Irf1/
Nras
5 Down
Pro-inflammatory and Anti-inflammatory
Response Are Tightly Regulated in the
Early Stages of Response
DCs undergo a complex maturation process that involves
upregulation of MHC and co-stimulatory molecules. The
activation events are accompanied by the secretion of cytokines
that will act in an autocrine and paracrine manner impacting
not only the DC‘s phenotype, but most immune cells equipped
with the respective receptors as well. Considering that most
of the pathways differently expressed between Qβ(RNA) and
Qβ(1668) were related to immune responses triggered by
cytokines, the subsequent analysis was focused on assessing
cytokine production.
Aiming to have a better understanding of the cytokines
being differentially regulated in response to immunization,
we first analyzed RNA expression levels for cytokines in
detail (Figure 7A). Based on the 30 selected cytokines the
resulting clustering analysis of the expression level of each
cytokine displayed an expression pattern correlated to the
type of TLR ligand packaged in the VLP given as a vaccine.
The group receiving Qβ(1668) up-regulated expression of
several pro-inflammatory cytokines such as INF-γ, IL-2, and
several chemokine receptors as well as IL-1R, IL-12R, whilst
down-regulating IL-4, a cytokine known to promote Th2
polarization. The group receiving Qβ(RNA) clustered closer to
Qβ(o) instead of Qβ(1668). Differences were especially seen for
the cytokines IL-10, CCL2, and IL-1 to name a few.
In order to validate the mRNA expression of cytokines, key
cytokines secreted 24 h following in vivo immunization were
measured by Milliplex (Figure 7B). Mice were immunized
following the same regimen stated previously, 24 h later
splenocytes were collected and incubated for further 12 h.
Qβ(1668) induced higher levels of secretion of several
inflammatory and some anti-inflammatory cytokines. As
expected, most of the cytokines followed the same trend as seen
in the RNAseq data. As examples may serve pro-inflammatory
cytokines and chemokines, such as IL1-α, IL1-β, IL-6, and CCL2,
and IL-10 as anti-inflammatory cytokine. The Th9-associated
cytokine IL-9 on the other hand was produced in higher levels
by the Qβ(RNA) and Qβ(o) immunized groups, corresponding
to the RNA expression data and showing the dominating
Th1-biased response induced by CpG 1668. Contrary to the
RNA expression data, IFN-γ was mostly produced in response to
Qβ containing RNA, which could be an indication that there are
other cells than DCs producing IFN-γ in response to the RNA
compared to CpG.
Aiming to identify cytokines produced 24 h post
immunization that could be correlated to T cell responses, a
pairwise correlation analysis of the average cytokine production
and outcome of T cell responses as measured by tetramer
staining was performed. The correlation matrix (Figure 7C)
showed that the tested variable of tetramer staining was
positively correlated to IL-6, IL-10, CXCL10, CCL2, IL-1a,
IL-1b, CXCL1, and TNF-α. The cytokine IL-9 and IFN-γ
were negatively correlated to tetramer staining while the
chemokines CXCL2, CCL3, CCL4, and growth factor G-CSF
did not reach statistical significance (p < 0.01). Of note,
cytokines IL-2, IL-4, IL-7, IL-12p40, and IL-12p70 and IL-15
had also been measured but were below the detection limit of
the assay.
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FIGURE 7 | Immunization with the different VLPs leads to distinct Cytokines production. (A) Expression data (multi mapped counts per million) of selected cytokines
24 h post immunization in splenic DCs (+12 h incubation). Hierarchical clustering of top 30 differently expressed cytokines. Clustering calculated based on the
Euclidean distances using complete linkage clustering. (B) Secreted cytokines by splenocytes 24 h post immunization. Values represented as mean + SEM. N = 3
mice. (C) Correlation matrix of cytokines secreted by splenocytes 24 h post immunization. Positive correlations are displayed in blue and negative correlations in red
color. Color intensity and the size of the circle are proportional to the correlation coefficients. Legend colors shows the correlation coefficients and the corresponding
colors. Correlation calculated using Pearsons coefficient. Correlations with significance p > 0.01 are depicted in white.
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FIGURE 8 | CCL2 is up-regulated in DCs immunized with Qβ(1668) that modulates CTL responses. (A) CCL2 mRNA expression 24 h following immunization with
Qβ(1668) or Qβ in comparison to Qβ(o). Data is represented as mean fold change. N = 3 mice per group. (B) CCL2 secreted in supernatants of splenocytes isolated
after 24 h of immunization and 12 h of incubation in vitro. N = 3 mice per group. (C) CD86 expression on BMDCs pulsed with VLPs for 3 h p33-specific tetramer
staining of CD8+ T cells. BMDCs were generated from pooled bone marrow from 2 mice. 3 individual replicates per condition. (D) Tetramer staining of CD8+ T cells 7
days post immunization. (E) ICS staining of CD3+CD8+ T cells 7 days post vaccination. 6 h stimulation with p33 peptide. Data represented as Mean + SEM of 2
combined experiments. Statistical analysis was performed by calculating the Z score of the combined p-values of the two independent experiments. *p < 0.04,
**p < 0.02.
Interestingly, type B CpG had been consistently described as
an inducer of IL-12 secretion by us and others (29), namely
when testing in an in vitro setting. In our in vivo experimental
setting, however, we were unable to detect IL-12 at this time
point. We have also observed a higher production level of
GM-CSF in the Qβ(1668) receiving group, a cytokine that is
critical for DC activation and is typically produced by naïve T
cells and NK cells (30). These data underpin the complexity of
the orchestration of T cell responses in response to vaccines
and the complex cross-modulation of innate and adaptive
immune system.
CCL2 Modulates CD8+ T Cell Responses
Induced by Qβ(CpG)
Considering the evident up-regulation of CCL2 mRNA on DCs,
the higher levels of CCL2 in the supernatant of splenocytes from
mice immunized with Qβ(1668) (Figures 8A,B, respectively) and
the positive correlation of CCL2 production and T cells responses
(Figure 7C) we sought to investigate the role of CCL2 in CTL
responses in vivo.
First, we investigated upregulation of activation makers
in BMDCs from CCL2−/− vs. control mice in response to
VLPs. CD86 upregulation was reduced in response to both
Qβ(RNA) and Qβ(1668). To evaluate the impact of CCL2
on CTL responses, sex and age matched CCL2−/− mice
and WT counterparts were immunized with Qβ(RNA)-p33
or Qβ(1668)-p33 and T cell responses were subsequently
assessed 7 days later. CCL2−/− mice showed a reduction in
the clonal expansion of p33 specific T cells (Figure 8). In
addition to that, the capacity of those cells to produce IFN-
γ was reduced compared to the WT (Figure 8E). The reduced
response likely reflects a modulatory effect of CCL2 on the
T cell response.
DISCUSSION
In the present study, the modulation of the innate immune
response mediated by VLPs packaging TLR ligands was
investigated and characterized in the context of vaccines. The
outcome of immunizations employing VLPs loaded with PRR
ligands was evaluated and correlated to the early events in DCs
orchestrating subsequent adaptive responses mediated by T cells.
We show here that packaging CpGs into VLP alters their
endosomal trafficking. Packaged CpG is retained for longer
periods of time in endosomal compartments before reaching
lysosomes, which may impact the immune response as seen by
differential cytokine production induced by free and packaged
versions of CpGs.
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The initial innate immune response mediated by DCs
influences subsequent adaptive immune responses; here, the early
transcriptional signature in DCs in response to immunization
was characterized and we correlated these findings to the
observed T cell responses. Functional analysis of the genes
expressed in response to the different VLP formulations indicated
important immune pathways being differently regulated 24 h
post immunization.
From those pathways, CCL2 was selected for further
investigation due to its markedly distinct expression in response
to CpG and its relevance to the overall immune response.
We found that CCL2 chemokine produced by DCs 24 h after
immunization onwards modulates the quality of the cytokines
produced by T cells in a later stage of the response. CCL2 has
been shown to support DC-maturation (31) and the recruitment
and modulation of IFN-γ production by T cells (32). The
immune response seen in CCL2−/− mice was only slightly
reduced, and observation may be explained by the redundancy
of the chemokine system. CCL2 signals through CCR2, a
receptor shared with several other chemokines; lack of CCL2
may therefore have been partly compensated by re-modeling
of the milieu of chemokines that maintains T cell responses.
In addition to CCL2, other chemokines and cytokines were
positively correlated to CTL responses in our model, including
pro-inflammatory cytokines and also IL-10, a cytokine known
for its anti-inflammatory activity on T cells. IL-10 is traditionally
considered as a negative regulator of protective immune
responses. Our data here support recent findings indicating a
more multifaceted behavior of IL-10 (33). IL-10 analyzed in the
complex cytokine milieu induced in vivo seems to support CTL
responses, by either modulating the response to avoid excessive
immune activation or yet, by controlling suppressive subsets
of CD4+ T cells (34). Alternatively, IL-10 may be induced by
pro-inflammatory cytokines that enhance CTL-responses and
IL-10 may not causally linked to enhanced CTL responses but
merely reflect the presence of these other cytokines. Finally,
we found no role for STING or MAVS in the VLP-induced
CTL responses.
In summary, this work contributes to the understanding
of DC-mediated immune responses in the context of vaccines
and their development and further establishes the potential
of VLPs to modulate the immune response. Finally, our data
support the notion that immune responses are orchestrated
by a complex milieu of cytokines and immune cells and
that there are several processes occurring in parallel that
shape and direct the overall response. Understanding such
processes is a challenging but rewarding endeavor as many
therapeutic clues and basic knowledge can be derived
from research of this kind. Moreover, VLPs and CpGs are
currently being employed for clinical use, especially in vaccine
formulation; we hope to contribute to the understanding of
the immune activity of both compounds and facilitate their use
as vaccines.
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Figure S1 | STING −/−, MAVS −/−, and age and sex matched C57BL/6 wild
type mice were vaccinated s.c. with 50 µg of VLP-p33 (A) p33-specific
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Mean ± SEM of n = 3 mice/group. Statistical significance was measured by
unpaired two tailed t-tests followed by Bonferroni-Dunn’s correction for multiple
testing. ∗p < 0.01, ∗∗∗p < 0.0009. Data is representative of 3
independent experiments.
Figure S2 | Gene Ontology of genes belonging to the sub-ontology
“Biological Processes.” Genes differently expressed between DCs from
immunized mice receiving (A) Qβ(RNA) vs. Qβ(o) and (B) Qβ(o) vs. Qβ(1668),
and (C) Qβ(RNA) vs. Qβ(1668). –log 10 of q values. % of DX: percentage
of genes differently expressed. Data was analyzed using the package DAVID
for GO analysis.
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